Join
Live feed
·
PRReleasevia Quantisnow
MBX Biosciences Inc. logo

CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

ByQuantisnow·Wall Street's wire, on your screen.
MBX· MBX Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MBX (MBX Biosciences Inc.) and more on Quantisnow.